Skip to content
VectorGene
vi
Nội dung lâm sàng và kỹ thuật được cung cấp bằng tiếng Anh.

CHGB · Partner-reported service scope

Alzheimer's Disease Early Screening

Plasma multi-biomarker assessment including the Aβ1-42/Aβ1-40 ratio and p-tau217, identifying individuals who may require confirmatory PET or CSF evaluation.

Method
Mass spectrometry
Hospital room with bed and clinical equipment. Illustrative stock photograph.
Hospital room with bed and clinical equipment

CHGB · Partner-reported

Service capabilities

The following scope is reported by the partner. Quantities describe the partner portfolio and do not represent VectorGene’s own track record.

Aβ1-42 / Aβ1-40 ratio
p-tau217
Confirmatory pathway design
PET or CSF referral criteria.
Family risk stratification

Explore the related platform.

Advanced genomic testing platforms for precision oncology, inherited disease analysis, pathogen sequencing, microbiome analysis and population-level genomic programmes.

Genomics & NGS Testing
Varies by jurisdiction

Diagnostic testing is regulated differently in every jurisdiction. VectorGene supports local validation and accreditation; the regulatory dossier remains owned by the local institution.

Distinguish specialist assessment from population screening.

The intended patient population matters as much as the biomarker. Review the proposed assay’s own evidence and status, and describe how a result would be combined with specialist assessment. Avoid transferring the indication or clearance of a different commercial test to this partner service.

The blood test cleared by FDA in May 2025 was intended to aid assessment of symptomatic adults aged 55 and older in specialised care. FDA explicitly described it as unsuitable for screening or standalone diagnosis. That clearance does not establish the status of the partner service on this page.

FDA: FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease

External references explain the wider context. They do not verify or endorse the supplied VectorGene or partner offering.

Questions for the programme brief

  1. Which assay and population?

    Request the named assay, biomarkers, intended age group, symptom criteria and documentation of its permitted use.

  2. Which clinical pathway?

    Identify the specialist service, additional evaluations and management of indeterminate or conflicting findings.

  3. What supports the claim?

    Review assay-specific evidence, sample handling, analytical performance and how the report communicates limitations.

What to prepare for review
  • Named assay and intended-use documentation
  • Specialist assessment and referral pathway
  • Validation evidence and example report

Working environments

Clinical and laboratory settings.

Illustrative stock photography provides context for the people, processes and working environments behind this capability.

Blood sample tubes in a laboratory rack. Illustrative stock photograph.
Blood sample tubes in a laboratory rack
Document review at a desk. Illustrative stock photograph.
Document review at a desk
Hospital reception and clinical entry point. Illustrative stock photograph.
Hospital reception and clinical entry point
Data centre cabinets beneath blue cabling. Illustrative stock photograph.
Data centre cabinets beneath blue cabling

Start a conversation

Discuss Alzheimer's Disease Early Screening

This service will be retained as context for your enquiry. Choose the platform or support area you want to develop at your institution.
Partner with us